Peer-reviewed veterinary case report
CpG oligonucleotide boosts cat immune defense against five virus types
By Robert-Tissot, Céline et al.·Published in Veterinary research·2012·Vetsuisse Faculty·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Stimulation with a class A CpG oligonucleotide enhances resistance to infection with feline viruses from five different families.
- Species:
- cat
Plain-English summary
A study found that giving domestic cats a specific treatment called CpG oligonucleotide (CpG-A) can help boost their immune response against various viral infections. This treatment increased the cats' ability to fight off viruses from five different families, including those that cause serious illnesses. When cats received this treatment under the skin, their immune systems showed a significant increase in protective responses within 24 hours. This suggests that CpG-A could be a promising way to help protect cats in shelters and catteries from dangerous viral infections.
People also search for: cat viral infection prevention · CpG-A treatment for cats · boosting cat immune system · feline virus protection · cat shelter health measures
Abstract
Domestic cats are commonly affected by viral pathogens that induce lengthy infections with fatal outcomes. Prevention of viral propagation is of primordial importance in shelters and catteries, where cats from different backgrounds have narrow contacts. Oligonucleotides (ODN) containing cytosine-phosphate-guanosine motifs of class A (CpG-A) are highly potent synthetic inducers of innate antiviral mechanisms. The aim of this study was to test their ability to modulate innate immune responses and prevent viral replication as stand-alone agents in the domestic cat. CpG-A stimulation of feline peripheral blood mononuclear cells (PBMCs) enhanced their proliferation, increased the presence of co-stimulatory molecules on their surface and influenced their gene expression profiles in an antiviral orientation. Incubation of the supernatants of CpG-A stimulated PBMCs with feline cell lines of epithelial and fibroblastic origin induced expression of the antiviral myxovirus resistance (Mx) gene in these target cells, which also showed enhanced resistance to feline viruses from five distinct families, namely Coronaviridae, Herpesviridae, Caliciviridae, Parvoviridae, and Retroviridae. Most importantly, subcutaneous administration of CpG-A in domestic cats systemically increased the expression of Mx, reaching maximal levels within 24 h. Plasma from treated cats could furthermore inhibit viral replication in vitro. Altogether, our data highlight the promising potential of CpG-A to induce a preventive antiviral state in the cat and to protect feline populations against a broad range of virus infections.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22906110/